POMBILITI 105 mg, powder for concentrate for infusion bottle, 20 ml
Active ingredients: CIPAGLUCOSIDASE ALFA
Commercialized according to BDPMDispensing in France: Prescription only
Powder for concentrate for infusionbottle, 20 mlintraveineuse
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- POMBILITI 105 mg, poudre pour solution à diluer pour perfusion
- Pharmaceutical form
- poudre pour solution à diluer pour perfusion
- Route of administration
- intraveineuse
- Presentation description
- 1 flacon en verre de 20 mL
- Marketing authorisation holder
- AMICUS THERAPEUTICS EUROPE (IRLANDE)
- Reimbursement according to BDPM
- —
- Approval for use in healthcare institutions
- non
- Commercialization declaration date
- 9 Nov 2023
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Prescribed by a hospital doctor
- Enhanced ANSM monitoring
- Yes
BDPM identifiers
CIS
64427538CIP73027261CIP133400930272619Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| CIPAGLUCOSIDASE ALFApoudre | 105 mg · un flacon | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.